Treatment of acute schizophrenia with paliperidone ER: predictors for treatment response and benzodiazepine use.

摘要: The Paliperidone ER Treatment in Acute Intervention (PERTAIN) study was designed to explore treatment response, tolerability, and safety of flexible doses paliperidone patients with schizophrenia admitted for an acute exacerbation. This paper addresses a secondary analysis PERTAIN data predictors dosing, concomitant benzodiazepine use. prospective, multicenter, phase 3b, open-label, single-arm, 6-week used (3 12mg once daily) treat hospitalized exacerbation schizophrenia, reflecting more closely daily clinical practice. Predictive models were evaluated benzodiazepines as distinct independent variables. For the explanatory variables, stepwise logistic regression used, taking into account patient age, gender, body mass index, diagnosis duration number prior hospitalizations, psychotic symptoms (PANSS), disease severity (CGI-S), functioning (PSP) at baseline. Early response (defined within 2weeks initiation) also predictor. Clinical ≥30% decrease PANSS total score ≥1 point CGI-S from baseline endpoint) predicted by early (p<0.001) there trend paranoid vs. other types predict (p=0.0525). High ≥50% ≥2 points high higher CGI-S, or female gender. More severely ill twice likely be treated concomitantly benzodiazepine.